Takeda Pharmaceutical (NYSE:TAK) Announces Earnings Results, Beats Expectations By $0.08 EPS

Takeda Pharmaceutical (NYSE:TAK) posted its earnings results on Thursday. The company reported $0.42 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.08, Zacks reports. Takeda Pharmaceutical had a return on equity of 10.00% and a net margin of 6.49%. Takeda Pharmaceutical updated its FY 2024 guidance to 3.330-3.330 EPS.

Takeda Pharmaceutical Stock Down 2.2 %

TAK opened at $13.41 on Friday. The firm has a market cap of $42.65 billion, a P/E ratio of 23.11, a price-to-earnings-growth ratio of 0.25 and a beta of 0.51. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.77 and a current ratio of 1.28. The business has a 50 day moving average price of $13.31 and a 200 day moving average price of $13.88. Takeda Pharmaceutical has a twelve month low of $12.57 and a twelve month high of $15.08.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.